Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND & AIMS">Genetic factors associated with non-alcoholic fatty liver disease (NAFLD) remain incompletely understood. To date, most genome-wide association studies (GWASs) have adopted radiologically assessed hepatic triglyceride content as the reference phenotype and so cannot address steatohepatitis or fibrosis. We describe a GWAS encompassing the full spectrum of histologically characterised NAFLD.</AbstractText>METHODS: <AbstractText Label="METHODS">The GWAS involved 1,483 European NAFLD cases and 17,781 genetically matched controls. A replication cohort of 559 NAFLD cases and 945 controls was genotyped to confirm signals showing genome-wide or close to genome-wide significance.</AbstractText>RESULTS: <AbstractText Label="RESULTS">Case-control analysis identified signals showing p values ≤5 × 10-8 at 4 locations (chromosome [chr] 2 GCKR/C2ORF16; chr4 HSD17B13; chr19 TM6SF2; chr22 PNPLA3) together with 2 other signals with p <1 × 10-7 (chr1 near LEPR and chr8 near IDO2/TC1). Case-only analysis of quantitative traits showed that the PNPLA3 signal (rs738409) had genome-wide significance for steatosis, fibrosis and NAFLD activity score and a new signal (PYGO1 rs62021874) had close to genome-wide significance for steatosis (p = 8.2 × 10-8). Subgroup case-control analysis for NASH confirmed the PNPLA3 signal. The chr1 LEPR single nucleotide polymorphism also showed genome-wide significance for this phenotype. Considering the subgroup with advanced fibrosis (≥F3), the signals on chr2, chr19 and chr22 maintained their genome-wide significance. Except for GCKR/C2ORF16, the genome-wide significance signals were replicated.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">This study confirms PNPLA3 as a risk factor for the full histological spectrum of NAFLD at genome-wide significance levels, with important contributions from TM6SF2 and HSD17B13. PYGO1 is a novel steatosis modifier, suggesting that Wnt signalling pathways may be relevant in NAFLD pathogenesis.</AbstractText>LAY SUMMARY: <AbstractText Label="LAY SUMMARY">Non-alcoholic fatty liver disease is a common disease where excessive fat accumulates in the liver and may result in cirrhosis. To understand who is at risk of developing this disease and suffering liver damage, we undertook a genetic study to compare the genetic profiles of people suffering from fatty liver disease with genetic profiles seen in the general population. We found that particular sequences in 4 different areas of the human genome were seen at different frequencies in the fatty liver disease cases. These sequences may help predict an individual's risk of developing advanced disease. Some genes where these sequences are located may also be good targets for future drug treatments.</AbstractText>

Characterization by polygenic risk score of a dysmetabolic population of Southern Italy

Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables

Genetic risk scores and personalization of care in fatty liver disease

Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease

Genetics Is of the Essence to Face NAFLD

Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population

Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD

Differential effects of genetic polymorphism on comorbid disease in metabolic dysfunction-associated steatotic liver disease

Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease

Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver‐Related Events in Metabolic Dysfunction‐Associated Steatotic Liver Disease

A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease

Role of genetic modification of the PNPLA3 gene in predicting metabolically unhealthy obesity and metabolic associated fatty liver disease in children

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

Effect of common genetic variants on the risk of cirrhosis in non‐alcoholic fatty liver disease during 20 years of follow‐up

A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry

Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease

The body mass index increases the genetic risk scores' ability to predict risk of hepatic damage in European adolescents: The HELENA study

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes

PNPLA3 rs738409 Genetic Variant Inversely Correlates with Platelet Count, Thereby Affecting the Performance of Noninvasive Scores of Hepatic Fibrosis

Integrating PNPLA3 into clinical risk prediction

The rs2294918 E434K variant modulates PNPLA3 expression and liver damage.